دورية أكاديمية
Efficacy of treatment of chronic obstructive pulmonary disease after virus-induced exacerbations ; Эффективность терапии хронической обструктивной болезни легких после вирус-ассоциированного обострения
| العنوان: | Efficacy of treatment of chronic obstructive pulmonary disease after virus-induced exacerbations ; Эффективность терапии хронической обструктивной болезни легких после вирус-ассоциированного обострения |
|---|---|
| المؤلفون: | L. A. Shpagina, O. S. Kotova, I. S. Shpagin, G. V. Kuznetsova, S. A. Karmanovskaya, L. A. Panacheva, E. V. Anikina, Л. А. Шпагина, О. С. Котова, И. С. Шпагин, Г. В. Кузнецова, С. А. Кармановская, Л. А. Паначева, Е. В. Аникина |
| المساهمون: | Federal budget funds for the implementation of state task No.056-00034-21-00 were used, Исследование осуществлялось за счет средств федерального бюджета на исполнение государственного задания № 05600034-21-00 |
| المصدر: | PULMONOLOGIYA; Том 33, № 6 (2023); 739-749 ; Пульмонология; Том 33, № 6 (2023); 739-749 ; 2541-9617 ; 0869-0189 |
| بيانات النشر: | Scientific and Practical Journal “PULMONOLOGIYA” LLC |
| سنة النشر: | 2023 |
| المجموعة: | Pulmonology (E-Journal) / Пульмонология |
| مصطلحات موضوعية: | длительно действующие антихолинергические препараты, exacerbation, respiratory viral infection, inhaled corticosteroid, long-acting β2-agonist, longacting muscarinic antagonist, обострение, респираторная вирусная инфекция, ингаляционные глюко-кортикостероиды, длительно действующие β2-агонисты |
| الوصف: | Viral respiratory infection is one of the main etiologic factors for acute exacerbations of COPD (AECOPD). The disease course after virus-associated AECOPD and the response to treatment have not been studied adequately.The aim was to evaluate the efficacy of single-inhaler triple therapy (SITT) of long-acting anticholinergic drugs (LAMA)/long-acting β2-agonists (LABA) of adrenergic receptors/inhaled glucocorticosteroids (ICS) on COPD symptoms, lung function, exercise tolerance, and inflammatory activity compared with multiple-inhaler triple therapy (MITT) after a virus-associated COPD exacerbation.Methods. This was an observational prospective cohort study of COPD patients (spirographус criterion) hospitalized for AECOPD with viral (n = 60) or viral-bacterial (n = 60) infection. The comparison group included patients with bacterial AECOPD (n = 60). Viral infection was diagnosed by PCR-RT of sputum or bronchoalveolar lavage fluid for RNAs of rhinovirus, RS virus, influenza A and B viruses, or SARS-CoV-2 virus. Bacterial infection was demonstrated by sputum purulence and/or procalcitonin test results and/or standard culture data. During AECOPD, blood cytokines were measured by ELISA. The patients were treated with SITT (investigational treatment) or MITT (comparison treatment) of LAMA/LABA/ICS in real-world clinical practice. The follow-up started 4 weeks after AECOPD regression and discharge from hospital.Results. After 52 weeks of treatment, FEV1 decline was smaller than in the SITT group. Differences from the MITT group were greater in patients with viral AECOPD (–69 (–75; –10) ml vs –75 (–78; –72) ml) or viral-bacterial AECOPD (–67.5 (–69; –37.25) ml vs –75.5 (–84; –70.25) ml). An increase in DLCO/Va, 6-minut walk test (6MWT) results, a decrease in bronchodilation coefficient, blood eosinophils and fibrinogen was seen only in subjects who received SITT and had viralor viral-bacterial AECOPD. A multiple regression model revealed a direct association between blood interleukin-5 and improvement in FEV1 (В = ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | Russian |
| العلاقة: | https://journal.pulmonology.ru/pulm/article/view/4372/3578Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4372/2183Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4372/2184Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4372/2185Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4372/2186Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4372/2187Test; GBD 2019 Chronic Respiratory Diseases Collaborators. Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the global burden of disease study 2019. EClinicalMedicine. 2023; 59: 101936. DOI:10.1016/j.eclinm.2023.101936.; Федеральная служба государственной статистики (Росстат). Российский статистический ежегодник: статистический сборник. М; 2022. Доступно на: https://rosstat.gov.ru/storage/mediabank/Ejegodnik_2022.pdfTest; Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 963–974. DOI:10.2147/COPD.S67283.; Быстрицкая Е.В., Биличенко Т.Н. Заболеваемость, инвалидность и смертность от болезней органов дыхания в Российской Федерации (2015–2019). Пульмонология. 2021; 31 (5): 551–561. DOI:10.18093/0869-0189-2021-31-5-551-561.; Brightling C., Greening N. Airway inflammation in COPD: progress to precision medicine. Eur. Respir. J. 2019; 54 (2): 1900651. DOI:10.1183/13993003.00651-2019.; Шпагина Л.А., Котова О.С., Сараскина Л.Е., Ермакова М.А. Особенности клеточно-молекулярных механизмов профессиональной хронической обструктивной болезни легких. Сибирское медицинское обозрение. 2018; 110 (2): 37–45. DOI:10.20333/2500136-2018-2-37-45.; Wu J.J., Xu H.R., Zhang Y.X. et al. The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a meta-analysis and system review. BMC Pulm. Med. 2020; 20 (1): 103. DOI:10.1186/s12890-020-1126-x.; Зыков К.А., Овчаренко С.И., Авдеев С.Н. и др. Фенотипические характеристики пациентов с хронической обструктивной болезнью легких, имеющих стаж курения, в Российской Федерации: данные исследования POPE-study. Пульмонология. 2020; 30 (1): 42–52. DOI:10.18093/0869-0189-2020-30-1-42-52.; Müllerová H., Marshall J., de Nigris E. et al. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis. Adv. Respir. Dis. 2022; 16: 17534666221113647. DOI:10.1177/17534666221113647.; Ghebre M.A., Pang P.H., Diver S. et al. Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. J. Allergy Clin. Immunol. 2018; 141 (6): 2027–2036.e12. DOI:10.1016/j.jaci.2018.04.013.; Hurst J.R., Han M.K., Singh B. et al. Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. Respir. Res. 2022; 23 (1): 213. DOI:10.1186/s12931-022-02123-5.; Visseaux B., Burdet C., Voiriot G. et al. Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016. PLoS One. 2017; 12 (7): e0180888. DOI:10.1371/journal.pone.0180888.; Jafarinejad H., Moghoofei M., Mostafaei S. et al. Worldwide prevalence of viral infection in AECOPD patients: a meta-analysis. Microb. Pathog. 2017; 113: 190–196. DOI:10.1016/j.micpath.2017.10.021.; Liao K.M., Chen Y.J., Shen C.W. et al. The influence of influenza virus infections in patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2022; 17: 2253–2261. DOI:10.2147/COPD.S378034.; Mahmud S.M.H., Al-Mustanjid M., Akter F. et al. Bioinformatics and system biology approach to identify the influences of SARS-CoV-2 infections to idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease patients. Brief. Bioinform. 2021; 22 (5): bbab115. DOI:10.1093/bib/bbab115.; Guo-Parke H., Linden D., Weldon S. et al. Mechanisms of virus-induced airway immunity dysfunction in the pathogenesis of COPD disease, progression, and exacerbation. Front. Immunol. 2020; 11: 1205. DOI:10.3389/fimmu.2020.01205.; D'Anna S.E., Maniscalco M., Cappello F. et al. Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease. Ann. Med. 2021; 53 (1): 135–150. DOI:10.1080/07853890.2020.1831050.; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Хроническая обструктивная болезнь легких: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022; 32 (3): 356–392. DOI:10.18093/0869-0189-2022-32-3-356-392.; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis and Management of COPD: 2023 COLD Report. Available at: https://goldcopd.org/2023-gold-report-2Test/ [Assecced: August 04, 2023].; Авдеев С.Н., Айсанов З.Р., Архипов В.В. и др. Назначение / отмена ингаляционных глюкокортикостероидов у больных хронической обструктивной болезнью легких как терапевтический континуум в реальной клинической практике. Пульмонология. 2023; 33 (1): 109–118. DOI:10.18093/0869-0189-2023-33-1-109-118.; Alcázar-Navarrete B, Jamart L, Sánchez-Covisa J. et al. Clinical characteristics, treatment persistence, and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: a retrospective analysis in Spain. Chest. 2022; 162 (5): 1017–1029. DOI:10.1016/j.chest.2022.06.033.; Jones P.W., Harding G., Berry P. et al. Development and first validation of the COPD Assessment Test. Eur. Respir. J. 2009; 34 (3): 648–654. DOI:10.1183/09031936.00102509.; Чучалин А.Г., Айсанов З.Р., Чикина С.Ю. и др. Федеральные клинические рекомендации Российского респираторного общества по использованию метода спирометрии. Пульмонология. 2014; (6): 11–24. DOI:10.18093/0869-0189-2014-0-6-11-24.; Graham B.L., Brusasco V., Burgos F. et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur. Respir. J. 2017; 49 (1): 1600016. DOI:10.1183/13993003.00016-2016.; ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166 (1): 111–117. DOI:10.1164/ajrccm.166.1.at1102.; Puhan M.A., Chandra D., Mosenifar Z. et al. The minimal important difference of exercise tests in severe COPD. Eur. Respir. J. 2011; 37 (4): 784–790. DOI:10.1183/09031936.00063810.; Шпагина Л.А., Котова О.С., Шпагин И.С. и др. Клинико-функциональные особенности хронической обструктивной болезни легких после вирус-ассоциированных обострений. Терапевтический архив. 2023; 95 (3): 217–222. DOI:10.26442/00403660.2023.03.202086.; Singh D., Papi A., Corradi M. et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016; 388 (10048): 963–973. DOI:10.1016/s0140-6736(16)31354-x.; Lipson D.A., Barnhart F., Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018; 378 (18): 1671–1680. DOI:10.1056/NEJMoa1713901.; Ferguson G.T., Rabe K.F., Martinez F.J. et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir. Med. 2018; 6 (10): 747–758. DOI:10.1016/S2213-2600(18)30327-8.; Halpin D.M.G., Kendall R., Shukla S. et al. Cost-effectiveness of single- versus multiple-inhaler triple therapy in a UK COPD population: the INTREPID trial. Int. J. Chron. Obstruct. Pulmon. Dis. 2022; 17: 2745–2755. DOI:10.2147/COPD.S370577.; Ferguson G.T., Brown N., Compton C. et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir. Res. 2020; 21 (1): 131. DOI:10.1186/s12931-020-01360-w.; David B., Bafadhel M., Koenderman L., De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021; 76 (2): 188–195. DOI:10.1136/thoraxjnl-2020-215167.; Насонов Е.Л., ред. Российские клинические рекомендации: Ревматология. М.: ГЭОТАР-Медиа; 2020.; De Sadeleer L.J., Hermans F., De Dycker E. et al. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J. Clin. Med. 2018; 8 (1): 14. DOI:10.3390/jcm8010014.; RECOVERY Collaborative Group; Horby P., Lim W.S. et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 2021; 384 (8): 693–704. DOI:10.1056/NEJMoa2021436.; Ponce-Gallegos M.A., Ramírez-Venegas A., Falfán-Valencia R. Th17 profile in COPD exacerbations. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 1857–1865. DOI:10.2147/COPD.S136592.; Su Y., Gu H., Weng D. et al. Association of serum levels of laminin, type IV collagen, procollagen III N-terminal peptide, and hyaluronic acid with the progression of interstitial lung disease. Medicine (Baltimore). 2017; 96 (18): e6617. DOI:10.1097/MD.0000000000006617.; https://journal.pulmonology.ru/pulm/article/view/4372Test |
| DOI: | 10.18093/0869-0189-2023-33-6-739-749 |
| الإتاحة: | https://doi.org/10.18093/0869-0189-2023-33-6-739-749Test https://doi.org/10.1016/j.eclinm.2023.101936Test https://doi.org/10.2147/COPD.S67283Test https://doi.org/10.18093/0869-0189-2021-31-5-551-561Test https://doi.org/10.1183/13993003.00651-2019Test https://doi.org/10.20333/2500136-2018-2-37-45Test https://doi.org/10.1186/s12890-020-1126-xTest https://doi.org/10.18093/0869-0189-2020-30-1-42-52Test https://doi.org/10.1177/17534666221113647Test https://doi.org/10.1016/j.jaci.2018.04.013Test |
| حقوق: | Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC BY-NC 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). ; Авторы, публикующие статьи в данном журнале, соглашаются на следующее:Авторы сохраняют за собой авторские права и предоставляют журналу право первой публикации работы, которая после публикации автоматически лицензируется на условиях «Creative Commons Attribution License CC BY-NC 4.0", которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Условия передачи авторских прав: Автору (уполномоченному лицу) статьи следует скопировать форму Авторского договора, заполнить ее, отсканировать и прислать в редакцию. |
| رقم الانضمام: | edsbas.72728E0C |
| قاعدة البيانات: | BASE |
| DOI: | 10.18093/0869-0189-2023-33-6-739-749 |
|---|